We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
Read MoreHide Full Article
For Immediate Release
Chicago, IL – September 22, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cardinal Health Inc (NYSE:(CAH - Free Report) – Free Report), Penumbra Inc (NYSE:(PEN - Free Report) – Free Report), STAAR Surgical Company (Nasdaq:(STAA - Free Report) – Free Report), Masimo Corporation (Nasdaq:(MASI - Free Report) – Free Report) and Smith & Nephew plc (NYSE:(SNN - Free Report) – Free Report).
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
Over the past few months, the medical device space has been witnessing considerable upheaval owing to a confluence of factors. This has affected the fortunes of MedTech majors like Cardinal Health Inc (NYSE:(CAH - Free Report) – Free Report) and Penumbra Inc (NYSE:(PEN - Free Report) – Free Report).
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare. This is due to the fact that the GOP is making one final push on an Affordable Care Act repeal bill. The legislation, commonly referred to as Graham-Cassidy, aims to convert the Medicaid and premium subsidy dollars into a block-grant structure giving freedom of spending to states.
Past fortnight has witnessed extensive lobbying for and against the Graham-Cassidy bill by legislators to garner for and against the required 50 votes at the Senate. The trend is expected to continue till September 30. Earlier, Obamacare assured coverage to people with pre-existing ailments and restricted insurers from charging them based on health conditions.
The Senate Bill, however, will allow insurers to provide less-than-required coverage in states that get waivers for essential health benefits. However, the changes would not take effect until 2020 but would slash Medicaid budgets to the tune of almost 25% by 2026.
How Is MedTech Positioned?
Though the space remains volatile, there are many stocks in the MedTech domain that promise growth. The question now arises that how to pick safe stocks from the various industries of the MedTech space, in such a scenario. Within the Zacks Industry classification, it is broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into important areas like Medical - Instruments, Medical - Products and Medical - Dental Supplies.
Screening Criteria
In this article, we have picked a winner from each of the aforementioned areas that have traded higher than the S&P 500 index through the past one year. Also, based on their strong fundamentals, strategic implementation, planned execution and certain positive catalysts, they carry a huge upside potential and a high probability of outperforming the S&P 500 index in the coming days.
These stocks currently flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a VGM Score of A or B. Here, V stands for Value, G for Growth and M for Momentum and the score is a weighted combination of these three metrics. Such a score allows investors to eliminate negative aspects of stocks and select favorable ones. Their market capitalization is in multi-billions, testifying to their strong liquidity.
The 2017 estimate revision trend is significantly positive and earnings growth expectation is above the S&P 500. Finally, the industry’s lower-than-market positioning calls for more upside to offset any further volatility in Capitol Hill.
The Dental Supplies industry is currently ranked #185. It fell from last week’s #170. The industry has underperformed the S&P 500 by shedding 0.25% over the past month. The index, on the other hand, has gained 1.94%. By applying Zacks wisdom in this space, we are bullish on STAAR Surgical Company (Nasdaq:(STAA - Free Report) – Free Report).
Monrovia, CA-based Staar Surgical develops, manufactures and distributes products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. With a price surge of approximately 14.06% over the last six months, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 9.25% over the next five-year period. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Instruments industry is currently ranked #97. It fell from last week’s #88. The industry has underperformed the S&P 500 by registering a gain of only 0.97% over the past month. The index has gained only 1.94%. In this space, we are bullish on Masimo Corporation (Nasdaq:(MASI - Free Report) – Free Report).
Irvine, CA-based Masimo develops, manufactures and markets a family of non-invasive monitoring systems. With a price surge of approximately 27.26% year to date, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 11.10% over the next five-year period.
The Products industry is currently ranked #174, falling from #161 during last week. The industry has underperformed the S&P 500 by registering a gain of only 1.80% over the past month. The index on the other hand has rose 1.94%%. In this space, we are bullish on Smith & Nephew plc (NYSE:(SNN - Free Report) – Free Report).
Smith & Nephew, headquartered in London, U.K., is a manufacturer and distributor of advanced medical devices in the sports medicine, joint reconstruction, trauma and wound management areas. With a price surge of approximately 19.68% year to date, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 9.09% this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Cardinal Health, Penumbra, STAAR Surgical, Masimo and Smith & Nephew
For Immediate Release
Chicago, IL – September 22, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Cardinal Health Inc (NYSE:(CAH - Free Report) – Free Report), Penumbra Inc (NYSE:(PEN - Free Report) – Free Report), STAAR Surgical Company (Nasdaq:(STAA - Free Report) – Free Report), Masimo Corporation (Nasdaq:(MASI - Free Report) – Free Report) and Smith & Nephew plc (NYSE:(SNN - Free Report) – Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Thursday’s Analyst Blog:
Top MedTech Stocks Safe from Graham-Cassidy Repeal Bill
Over the past few months, the medical device space has been witnessing considerable upheaval owing to a confluence of factors. This has affected the fortunes of MedTech majors like Cardinal Health Inc (NYSE:(CAH - Free Report) – Free Report) and Penumbra Inc (NYSE:(PEN - Free Report) – Free Report).
The investment climate for medical device majors has become increasingly volatile due to political potshots in Capitol Hill, for and against Obamacare. This is due to the fact that the GOP is making one final push on an Affordable Care Act repeal bill. The legislation, commonly referred to as Graham-Cassidy, aims to convert the Medicaid and premium subsidy dollars into a block-grant structure giving freedom of spending to states.
Past fortnight has witnessed extensive lobbying for and against the Graham-Cassidy bill by legislators to garner for and against the required 50 votes at the Senate. The trend is expected to continue till September 30. Earlier, Obamacare assured coverage to people with pre-existing ailments and restricted insurers from charging them based on health conditions.
The Senate Bill, however, will allow insurers to provide less-than-required coverage in states that get waivers for essential health benefits. However, the changes would not take effect until 2020 but would slash Medicaid budgets to the tune of almost 25% by 2026.
How Is MedTech Positioned?
Though the space remains volatile, there are many stocks in the MedTech domain that promise growth. The question now arises that how to pick safe stocks from the various industries of the MedTech space, in such a scenario. Within the Zacks Industry classification, it is broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into important areas like Medical - Instruments, Medical - Products and Medical - Dental Supplies.
Screening Criteria
In this article, we have picked a winner from each of the aforementioned areas that have traded higher than the S&P 500 index through the past one year. Also, based on their strong fundamentals, strategic implementation, planned execution and certain positive catalysts, they carry a huge upside potential and a high probability of outperforming the S&P 500 index in the coming days.
These stocks currently flaunt a Zacks Rank #1 (Strong Buy) or 2 (Buy) and a VGM Score of A or B. Here, V stands for Value, G for Growth and M for Momentum and the score is a weighted combination of these three metrics. Such a score allows investors to eliminate negative aspects of stocks and select favorable ones. Their market capitalization is in multi-billions, testifying to their strong liquidity.
The 2017 estimate revision trend is significantly positive and earnings growth expectation is above the S&P 500. Finally, the industry’s lower-than-market positioning calls for more upside to offset any further volatility in Capitol Hill.
Medical - Dental Supplies
The Dental Supplies industry is currently ranked #185. It fell from last week’s #170. The industry has underperformed the S&P 500 by shedding 0.25% over the past month. The index, on the other hand, has gained 1.94%. By applying Zacks wisdom in this space, we are bullish on STAAR Surgical Company (Nasdaq:(STAA - Free Report) – Free Report).
Monrovia, CA-based Staar Surgical develops, manufactures and distributes products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. With a price surge of approximately 14.06% over the last six months, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 9.25% over the next five-year period. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medical – Instruments
The Instruments industry is currently ranked #97. It fell from last week’s #88. The industry has underperformed the S&P 500 by registering a gain of only 0.97% over the past month. The index has gained only 1.94%. In this space, we are bullish on Masimo Corporation (Nasdaq:(MASI - Free Report) – Free Report).
Irvine, CA-based Masimo develops, manufactures and markets a family of non-invasive monitoring systems. With a price surge of approximately 27.26% year to date, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 11.10% over the next five-year period.
Medical – Products
The Products industry is currently ranked #174, falling from #161 during last week. The industry has underperformed the S&P 500 by registering a gain of only 1.80% over the past month. The index on the other hand has rose 1.94%%. In this space, we are bullish on Smith & Nephew plc (NYSE:(SNN - Free Report) – Free Report).
Smith & Nephew, headquartered in London, U.K., is a manufacturer and distributor of advanced medical devices in the sports medicine, joint reconstruction, trauma and wound management areas. With a price surge of approximately 19.68% year to date, this Zacks Rank #2 stock is an attractive pick. Earnings for this company are expected to grow 9.09% this year.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.
Get the full Report on CAH - FREE
Get the full Report on PEN - FREE
Get the full Report on STAA - FREE
Get the full Report on MASI - FREE
Get the full Report on SNN - FREE
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com/
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.